Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a non-randomized, phase II, open-label study. The goal of this clinical research
study is to investigate how well sintilimab works in preventing high-risk oral premalignant
lesions cancerization.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University